Recent Patent based perspective on diagnostic and therapeutic interventions in Malignant Mesothelioma: Is Drug Repositioning knocking the door?
(2021) In Recent Patent on Anti-Cancer Drug Discovery 16(2). p.187-203- Abstract
- Background: Malignant Mesothelioma (MM), an orphan but aggressive malignancy of the mesothelial membrane, is a fatal tumor. Global epidemic related to malignant pleural mesothelioma is on the rise, so there is a need to explore novel biomarkers and ingenious therapeutic approaches to stalk this silent killer.
Objective: The main aim of the present review is to provide a consolidated overview of the recent active patents related to diagnosis and therapy in MM that will affect its future management.
Method: A search of existing literature was conducted from a PubMed database search. Recent patent information was fetched out from online accessible open-access databases. For related clinical trials, www.clinicaltrial.gov was... (More) - Background: Malignant Mesothelioma (MM), an orphan but aggressive malignancy of the mesothelial membrane, is a fatal tumor. Global epidemic related to malignant pleural mesothelioma is on the rise, so there is a need to explore novel biomarkers and ingenious therapeutic approaches to stalk this silent killer.
Objective: The main aim of the present review is to provide a consolidated overview of the recent active patents related to diagnosis and therapy in MM that will affect its future management.
Method: A search of existing literature was conducted from a PubMed database search. Recent patent information was fetched out from online accessible open-access databases. For related clinical trials, www.clinicaltrial.gov was searched.
Results: Patent search data showed 72 active patents related to diagnosis and therapy in the field of MM, which we classified into eight broad categories. Of these, a maximum of 17 patents was attributed to immunotherapy, and 13 each were attributed to "Drug Repositioning" and "Biological / synthetic" based candidates. The remaining 17 patents were distributed amongst virotherapy and various miscellaneous categories. A relatively low number of patents accounts for gene signature (7), epigenetics (3), and microRNA (2) based diagnosis and therapy. Furthermore, our clinical trial-based investigation revealed the futuristic impact of listed patents in MM patient management.
Conclusion: This review article has provided an overview of patent-based advancement in MM, which might become the apex in clinical settings in the future. Interestingly, immunotherapy and "drug repositioning" based therapy seems to be the front-runners in the race to provide relief. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/bc3b6069-2969-49c7-a0b8-5a656fd8e19b
- author
- Yadav, Vikas LU and Safari, Roghaiyeh
- publishing date
- 2021-07-11
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Recent Patent on Anti-Cancer Drug Discovery
- volume
- 16
- issue
- 2
- pages
- 187 - 203
- publisher
- Bentham Science Publishers
- external identifiers
-
- pmid:34254929
- scopus:85117208327
- ISSN
- 2212-3970
- DOI
- 10.2174/1574892816666210712113739
- language
- English
- LU publication?
- no
- id
- bc3b6069-2969-49c7-a0b8-5a656fd8e19b
- date added to LUP
- 2021-09-16 10:38:09
- date last changed
- 2022-04-27 03:53:25
@article{bc3b6069-2969-49c7-a0b8-5a656fd8e19b,
abstract = {{Background: Malignant Mesothelioma (MM), an orphan but aggressive malignancy of the mesothelial membrane, is a fatal tumor. Global epidemic related to malignant pleural mesothelioma is on the rise, so there is a need to explore novel biomarkers and ingenious therapeutic approaches to stalk this silent killer.<br/><br/>Objective: The main aim of the present review is to provide a consolidated overview of the recent active patents related to diagnosis and therapy in MM that will affect its future management.<br/><br/>Method: A search of existing literature was conducted from a PubMed database search. Recent patent information was fetched out from online accessible open-access databases. For related clinical trials, www.clinicaltrial.gov was searched.<br/><br/>Results: Patent search data showed 72 active patents related to diagnosis and therapy in the field of MM, which we classified into eight broad categories. Of these, a maximum of 17 patents was attributed to immunotherapy, and 13 each were attributed to "Drug Repositioning" and "Biological / synthetic" based candidates. The remaining 17 patents were distributed amongst virotherapy and various miscellaneous categories. A relatively low number of patents accounts for gene signature (7), epigenetics (3), and microRNA (2) based diagnosis and therapy. Furthermore, our clinical trial-based investigation revealed the futuristic impact of listed patents in MM patient management.<br/><br/>Conclusion: This review article has provided an overview of patent-based advancement in MM, which might become the apex in clinical settings in the future. Interestingly, immunotherapy and "drug repositioning" based therapy seems to be the front-runners in the race to provide relief.}},
author = {{Yadav, Vikas and Safari, Roghaiyeh}},
issn = {{2212-3970}},
language = {{eng}},
month = {{07}},
number = {{2}},
pages = {{187--203}},
publisher = {{Bentham Science Publishers}},
series = {{Recent Patent on Anti-Cancer Drug Discovery}},
title = {{Recent Patent based perspective on diagnostic and therapeutic interventions in Malignant Mesothelioma: Is Drug Repositioning knocking the door?}},
url = {{http://dx.doi.org/10.2174/1574892816666210712113739}},
doi = {{10.2174/1574892816666210712113739}},
volume = {{16}},
year = {{2021}},
}